You are here

Reblozyl

Bristol Myers says it needs another year to hit target for new drugs

Bristol Myers says it needs another year to hit target for new drugs

Reuters

Bristol Myers Squibb

Flag link:

Bristol Myers gets key FDA approval for bone marrow disease drug

Bristol Myers gets key FDA approval for bone marrow disease drug

BioPharma Dive

Bristol Myers Squibb

myelodysplastic syndromes

Flag link:

Bristol Myers data make case for earlier use of bone marrow disease drug

Bristol Myers data make case for earlier use of bone marrow disease drug

BioPharma Dive

Bristol Myers Squibb

myelodysplastic syndromes

clinical trials

Flag link:

FDA Accepts sBLA of BMS' Reblozyl

FDA Accepts sBLA of BMS' Reblozyl

Targeted Oncology

Bristol Myers Squibb

Flag link:

With positive trial results, Bristol Myers looks to widen use of blood disease drug

With positive trial results, Bristol Myers looks to widen use of blood disease drug

BioPharma Dive

Bristol Myers Squibb

myelodysplastic syndrome

Flag link:

Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date

Bristol Myers pulls plug on Reblozyl program for rare blood disorder, months after missed PDUFA date

Endpoints

Bristol Myers Squibb

beta thalassemia

Flag link:

Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod

Bristol Myers Squibb, Merck hit setback in bid to expand Reblozyl's anemia nod

Fierce Pharma

Bristol Myers Squibb

beta thalassemia

Flag link:

JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff

JPM 2022: Bristol Myers plots 3 blockbuster launches to counter Revlimid's patent cliff

Fierce Pharma

Bristol Myers Squibb

Flag link:

Merck & Co justifies paying up for Acceleron

Merck & Co justifies paying up for Acceleron

EP Vantage

Flag link:

Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches

Bristol Myers Squibb can grow through Revlimid generics, execs insist, pointing to key launches

Fierce Pharma

Bristol-Myers Squibb

Flag link:

Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches

Bristol Myers Squibb execs tout progress on Zeposia, Reblozyl and Onureg launches

Fierce Pharma

Bristol-Myers Squibb

Flag link:

CHMP backs BMS’ first-in-class anemia drug Reblozyl

CHMP backs BMS’ first-in-class anemia drug Reblozyl

Pharmaforum

Bristol-Myers Squibb

Flag link:

Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS

Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS

Pharmaceutical Business Review

Bristol-Myers Squibb

Flag link:

A Big Month Ahead for the FDA and Bristol-Myers Squibb

A Big Month Ahead for the FDA and Bristol-Myers Squibb

Motley Fool

Bristol-Myers Squibb

Flag link:

Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS

Bristol-Myers Squibb, Acceleron announce FDA advisory committee will review Reblozyl for use in patients with MDS

Pharmaceutical Business Review

Bristol-Myers Squibb

myelodysplastic syndromes

Flag link:

FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease

FDA Approves Celgene and Acceleron's Treatment for Rare Blood Disease

BioSpace

beta thalassemia

Flag link: